BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32446036)

  • 1. DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins.
    Brai A; Riva V; Saladini F; Zamperini C; Trivisani CI; Garbelli A; Pennisi C; Giannini A; Boccuto A; Bugli F; Martini M; Sanguinetti M; Zazzi M; Dreassi E; Botta M; Maga G
    Eur J Med Chem; 2020 Aug; 200():112319. PubMed ID: 32446036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X.
    Brai A; Ronzini S; Riva V; Botta L; Zamperini C; Borgini M; Trivisani CI; Garbelli A; Pennisi C; Boccuto A; Saladini F; Zazzi M; Maga G; Botta M
    Molecules; 2019 Nov; 24(21):. PubMed ID: 31690062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique Domain for a Unique Target: Selective Inhibitors of Host Cell DDX3X to Fight Emerging Viruses.
    Riva V; Garbelli A; Brai A; Casiraghi F; Fazi R; Trivisani CI; Boccuto A; Saladini F; Vicenti I; Martelli F; Zazzi M; Giannecchini S; Dreassi E; Botta M; Maga G
    J Med Chem; 2020 Sep; 63(17):9876-9887. PubMed ID: 32787106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: towards the next generation HIV-1 inhibitors.
    Radi M; Falchi F; Garbelli A; Samuele A; Bernardo V; Paolucci S; Baldanti F; Schenone S; Manetti F; Maga G; Botta M
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2094-8. PubMed ID: 22300661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
    Garbelli A; Riva V; Crespan E; Maga G
    Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RK-33 Is a Broad-Spectrum Antiviral Agent That Targets DEAD-Box RNA Helicase DDX3X.
    Yang SNY; Atkinson SC; Audsley MD; Heaton SM; Jans DA; Borg NA
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the magic bullet to the magic target: exploiting the diverse roles of DDX3X in viral infections and tumorigenesis.
    Riva V; Maga G
    Future Med Chem; 2019 Jun; 11(11):1357-1381. PubMed ID: 30816053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting host DEAD-box RNA helicase DDX3X for treating viral infections.
    Winnard PT; Vesuna F; Raman V
    Antiviral Res; 2021 Jan; 185():104994. PubMed ID: 33301755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.
    Brai A; Fazi R; Tintori C; Zamperini C; Bugli F; Sanguinetti M; Stigliano E; Esté J; Badia R; Franco S; Martinez MA; Martinez JP; Meyerhans A; Saladini F; Zazzi M; Garbelli A; Maga G; Botta M
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5388-93. PubMed ID: 27118832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
    Brai A; Martelli F; Riva V; Garbelli A; Fazi R; Zamperini C; Pollutri A; Falsitta L; Ronzini S; Maccari L; Maga G; Giannecchini S; Botta M
    J Med Chem; 2019 Mar; 62(5):2333-2347. PubMed ID: 30721061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
    Imamichi T
    Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication.
    Garbelli A; Radi M; Falchi F; Beermann S; Zanoli S; Manetti F; Dietrich U; Botta M; Maga G
    Curr Med Chem; 2011; 18(20):3015-27. PubMed ID: 21651478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a selective DDX3X inhibitor with newly developed quantitative high-throughput RNA helicase assays.
    Nakao S; Nogami M; Iwatani M; Imaeda T; Ito M; Tanaka T; Tawada M; Endo S; Cary DR; Ohori M; Imaeda Y; Kawamoto T; Aparicio S; Nakanishi A; Araki S
    Biochem Biophys Res Commun; 2020 Mar; 523(3):795-801. PubMed ID: 31954521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Interaction of Stress Granules, DDX3X, and IKK-α Mediates Multiple Functions in Hepatitis C Virus Infection.
    Pène V; Li Q; Sodroski C; Hsu CS; Liang TJ
    J Virol; 2015 May; 89(10):5462-77. PubMed ID: 25740981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation.
    Maga G; Falchi F; Radi M; Botta L; Casaluce G; Bernardini M; Irannejad H; Manetti F; Garbelli A; Samuele A; Zanoli S; Esté JA; Gonzalez E; Zucca E; Paolucci S; Baldanti F; De Rijck J; Debyser Z; Botta M
    ChemMedChem; 2011 Aug; 6(8):1371-89. PubMed ID: 21698775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ATP-Dependent RNA Helicase DDX3X Modulates Herpes Simplex Virus 1 Gene Expression.
    Khadivjam B; Stegen C; Hogue-Racine MA; El Bilali N; Döhner K; Sodeik B; Lippé R
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
    Nijhuis M; van Maarseveen NM; Boucher CA
    Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DExD/H-box helicases in HIV-1 replication and their inhibition.
    Heaton SM; Gorry PR; Borg NA
    Trends Microbiol; 2023 Apr; 31(4):393-404. PubMed ID: 36463019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
    Xu W; Zhao J; Sun J; Yin Q; Wang Y; Jiao Y; Liu J; Jiang S; Shao Y; Wang X; Ma L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4882-8. PubMed ID: 26055365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.